Time course of lamotrigine de-induction: Impact of step-wise withdrawal of carbamazepine or phenytoin

Epilepsy Research

Volumn 49, Issue 3, 2002, Pages 211-217

  Anderson, Gail D ^a   Gidal, Barry E ^b   Messenheimer, John A ^c   Gilliam, Frank G ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Carbamazepine; De induction; Drug interactions; Lamotrigine; Pharmacokinetics; Phenytoin

Indexed keywords

CARBAMAZEPINE; ENZYME INDUCING AGENT; LAMOTRIGINE; PHENYTOIN; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; ENZYME INDUCTION; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; CARBAMAZEPINE; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGE; PHENYTOIN; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; TRIAZINES; HUMANS; MIDDLE AGED;

EID: 0035990459     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00033-5     Document Type: Article

References (19)

1. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate
2. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes
3. Multicenter, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK lamotrigine elderly study group
4. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
5. Effect of age and gender on disposition of temazepam
6. An active-control trial of lamotrigine monotherapy for partial seizures
7. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy
8. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides
9. Oxazepam kinetics: Effect of age and sex
10. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data
11. Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal
12. Influence of sex and oral contraceptive steroids on paracetamol metabolism
13. Clinical implications of enzyme induction and enzyme inhibition
14. Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy
15. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy
16. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy
17. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin
18. Metabolically-based drug-drug interactions: Principles and mechanisms
19. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children